Evaluation Of Sexual Dysfunction Research Articles

Surveillance of Indonesian female sexual function after hysterectomy

Abstract Background: Sexual function is one component of quality of life that could be fulfilled by humans. Hysterectomy, which is an operative procedure in women, may cause disturbance in sexual function. Aim: This study aims to determine the surveillance of sexual function after hysterectomy. Methods: This is a cross-sectional study involving 92 gynecological tumor patients who had undergone a hysterectomy by open laparotomy procedure for at least 3 months. Evaluation of sexual dysfunction using the female sexual function index (FSFI-6) questionnaire, which assesses sexual function in the form of sexual disorder, sexual dysfunction, desire disorders, stimulation, orgasm disorders, and pain. The study was conducted in September–November 2018 in Dr. Cipto Mangunkusumo Hospital, Jakarta. The patients were divided into total and radical hysterectomy groups and whether castration was performed. Results: The total group had 71 total hysterectomy and 21 radical hysterectomy patients. Sexual dysfunction (radical hysterectomy 47.6%, n = 10/21; total hysterectomy 28.2%, n = 20/71; castration 33.8%, n = 24/71; and without castration 28.6%, n = 6/21); orgasmic disorders (total hysterectomy 28.2%, n = 20/71; radical hysterectomy 47.6%, n = 10/21; castration 33.8%, n = 24/71; without castration 28.6%, n = 6/21); and pain disorder (radical hysterectomy 28.6%, n = 6/21; compared with 9.9%, n = 7/71 total hysterectomy). Conclusion: No significant differences were found between sexual function after radical hysterectomy and total hysterectomy, as well as between the castration groups. Based on these findings, sexual function is an important reference for health professionals to be considered in conducting counseling before and after surgery.

Evaluation of sexual dysfunction in females with neck and upper back myofascial pain syndrome: a cross-sectional study.

Myofascial pain syndrome (MPS) is a prevalent chronic musculoskeletal pain disorder that is frequently encountered in clinical practice and can cause sexual dysfunction in women. While there have been studies examining sexual function in various painful rheumatic conditions, particularly fibromyalgia, no studies have been conducted specifically on primary MPS. In this context, we aimed to investigate the frequency of sexual intercourse and the factors associated with it in women diagnosed with MPS. The study was designed as a cross-sectional study at a tertiary rehabilitation center between May 2022 and April 2023. Forty-five consecutive sexually active women (mean age: 38.1 ± 6.8years) diagnosed with primary MPS were included in the study. They were compared to 45 healthy women of similar ages. The participants were interviewed regarding their weekly frequency of sexual intercourse and the importance of sexual life. Also, the Beck Depression Inventory (BDI) and the Visual Analog Scale (VAS) were assessed. The importance of sexual life score (p = 0.008), BDI (p < 0.001), VAS pain (p < 0.001), and VAS fatigue (p < 0.001) values were found to be lower in the patient group compared to the control group. The frequency of sexual intercourse was lower in the patient group, although this difference did not reach statistical significance (p = 0.083). In patients with a higher BDI score (≥ 17), the number of sexual intercourse was lower (p = 0.044), and the severity of fatigue was higher (p = 0.013). Significant associations were observed in MPS patients between the weekly frequency of sexual intercourse and VAS pain, VAS fatigue, BDI, and the importance of the sexual life score. A positive correlation was observed between the number of weekly sexual intercourses and the importance of the sexual life score (r = 0.577, p < 0.001), and negative correlations were found between BDI (r = -0.478, p < 0.001), VAS pain (r = -0.409, p < 0.001), and VAS fatigue (r = -0.439, p < 0.001). Patients with MPS should be assessed for depressive mood and fatigue, as these factors may contribute to sexual dysfunction. These results may also emphasize the importance of adopting a multidisciplinary approach in the management of MPS patients with concurrent sexual dysfunction. Clinicaltrials.gov identifier: NCT05727566.

Evaluation of Sexual Dysfunction and Related Factors in Iranian Men with Type 2 Diabetes: A Cross-Sectional Study

Objective: Recently, the association between sexual dysfunction (SD) and diabetes has been proven in various studies. The study aimed to determine the frequency of SD and identify risk factors related to SD in men with Type 2 diabetes mellitus (T2DM).&#x0D; Materials and Methods: The cross-sectional study was conducted on 114 men with T2DM who had referred to the Yazd Diabetes Center from 2019-2020. All of them filled out a standard questionnaire with a specified validity and reliability. The analysis was performed using ANOVA and Chi-square by SPSS, version 22 software.&#x0D; Results: The mean age of participants was 52.48 (±5.33). The SD frequency was 73.7%. The mean SD score was 17.89 (±12). There was a significant relationship between the total SD and neuropathy (P: 0.0001), retinopathy (P: 0.0001), nephropathy (P: 0.023), type of treatment (P: 0.0001), age (P: 0.0001) and addiction (P: 0.031). There was no significant relationship between the total SD score and hyperlipidemia (P: 0.371), hypertension (P: 0.683), Hb1Ac (P: 0.816), duration of diabetes (P: 0.101) and smoking (P: 0.29).&#x0D; Conclusion: Due to the high frequency of sexual dysfunction in men with T2DM, it is recommended that SD be considered as an important complication in these patients so that by identifying indicators related to this complication in patients with diabetes, sexual health clinics take the necessary measures to solve sexual problems in these patients.

Evaluation of Sexual Dysfunction in Brazilian Women with Infertility Undergoing Assisted Reproduction Treatment

Purpose: The increase in infertility around the world has a negative impact on sexual desire and function. The objective of this study was to evaluate the presence of sexual dysfunction in women diagnosed with infertility, comparing them with healthy controls. Methods: This is a cross-sectional study based on online questionnaire. Infertile women and healthy controls filled a questionnaire about epidemiological and assisted reproduction data. The infertile patients answered the Female Sexual Function Index (FSFI) and the Short-Form Health Survey (SF-12) questionnaires to assess sexual performance, physical, and mental health. The control group answered only to the FSFI. Results: The survey was completed by 357 subjects: 157 infertility patients and 200 matched controls. All medians of the FSFI domains of patients in the infertility group are lower (p=0.036) when compared to controls, especially the scores in the arousal and lubrication domains (p=0.003 and p&lt;0.0001, respectively). In this group, most are in good physical health and half are in good mental health. The depression rate was 12.7%. Patients who have depression have worse FSFI scores (p=0.009). Depression and sexual dysfunction were experienced by 27.4% (n=17) patients (p&lt;0.0001). Worse mental health was related to patients at higher risk for sexual dysfunction (p&lt;0.0001). Conclusion: In our sample of women undergoing infertility treatment, we found that the FSFI scores were significantly lower than in the control group, mainly in the arousal and lubrication domains. Additionally, it was found that the worse the mental health, the greater the possibility of sexual dysfunction in this group.

Sexual Dysfunction in Female Patients with Inflammatory Bowel Disease: An Overview.

Sexual dysfunction is common among females with inflammatory bowel disease and may result in issues involving intimacy, sexual activity, and satisfaction, as well both the formation and preservation of personal relationships. Risk factors for sexual dysfunction include select surgical interventions, medications, mental illnesses, and IBD-related intestinal and extraintestinal comorbidities. In addition, certain demographic factors such as age, disease type and activity may influence the severity of sexual dysfunction. Evaluation of sexual dysfunction may include the use of validated sexual functioning questionnaires, a brief mental health assessment, initial inquiry into vulvovaginal or perineal symptoms, and a gynecologic and GI-focused physical exam. An interdisciplinary care team involving IBD specialists, obstetrician-gynecologists, pelvic floor physical therapists, and primary care physicians may be best suited to provide optimal care and treatment recommendations for patients with sexual dysfunction. Options for management often include pelvic floor physical therapy, biofeedback, and mental health support. Further research is necessary to delineate the impact of IBD activity on sexual dysfunction, to determine if health outcome differences exist depending on surgical approaches utilized during J-pouch operations, and finally to evaluate the care and perceptions of patients with IBD who identify as sexual and gender minorities.

Sleep Disorders Are Associated with Female Sexual Desire and Genital Response - A U.S. Claims Database Analysis

To assess the association of common sleep disorders with female sexual dysfunction. We conducted a cross-sectional analysis using the TriNetX Diamond Network. Adult women diagnosed with insomnia, obstructive sleep apnea, or circadian rhythm sleep disorder were assessed to determine the association with female sexual dysfunction, hypoactive sexual desire disorder, female orgasmic disorder, and female sexual arousal disorder. A propensity-score matched control cohort for age, race, ethnicity, tobacco use, outpatient service utilization, obesity, hyperlipidemia, diabetes mellitus, hypertensive disease, ischemic heart disease, and surgical procedures on the female genital system was generated, excluding those with any sleep disorders, sleep deprivation, or morbid obesity with alveolar hypoventilation. All cohorts excluded those with any antidepressant or antipsychotic prescriptions. Our query yielded 1,317,491 women diagnosed with sleep apnea, 1,538,567 with insomnia, and 58,902 with circadian rhythm sleep disorder. Women with sleep apnea and insomnia had higher odds of hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorder compared to matched controls. Women with sleep apnea, insomnia, or circadian rhythm sleep disorder all had a significantly higher odds of female sexual dysfunction compared to matched controls. In this large cross-sectional analysis, sleep disorders were strongly associated with female sexual dysfunction. It is thus crucial for providers to screen for poor sleep when conducting a thorough evaluation for sexual dysfunction in women to diagnose highly prevalent sleep disorders and improve overall health.

Evaluation of Sexual Dysfunction in Hospitalized Post-Stroke Rehabilitation Patients

Introduction: Stroke-related factors seem to have significant effects on sexual functions in physical, biological, and psychosocial areas. This study aims to evaluate the factors affecting the sexual functions of patients after stroke.&#x0D; Material- methods: This study consisted of 51 (53.1%) male and 45 (46.9%) female patients. Socio -demographics and clinical features of the patients were documented. Sexual functions evaluated with Arizona Sexual Experiences Scale (ASES), International Index of Erectile function (IIEF) and Female Sexual Function Index (FSFI).&#x0D; Results: The mean age of men and women were 57.76±7.57, and 60.13±12.71 years, respectively. When the ASES cut-off point was 11, we found that 88.5% of the participants (84.3% in men and 93.3% in women) had sexual dysfunction. There was no significant difference between the frequency of sexual dysfunction in women and men (p=0.166, Pearson Chi-square Test). According to univariate ANOVA results, age (p=0.028) and BDI (p

Evaluation of sexual dysfunction in gynecologic cancer survivors using DSM-5 diagnostic criteria

BackgroundIn gynecologic cancer survivors, female sexual dysfunction (FSD) remains under-investigated. We attempted to estimate the prevalence of FSD associated with distress in gynecologic cancer survivors using diagnostic and statistical manual of mental disorders fifth edition (DSM-5) diagnostic criteria and to identify women at risk for FSD.MethodsWe conducted a cross-sectional analysis of premenopausal women aged 20–50 with various gynecologic cancers at least one year after treatment between January 2017 and December 2019. Data of sociodemographics and physical conditions were collected via face-to-face interview during outpatient clinic visits. The domains we used to define FSD were based on DSM-5 diagnostic criteria. Statistical analysis was carried out using Student's t test, Chi-square test and multiple logistic regression.ResultsA total of 126 gynecologic cancer survivors with a mean age of 42.4 years were included for analysis and 55 of them (43.7%) were diagnosed as having FSD associated with distress based on DSM-5 criteria. More than half of women (65.1%) reported decreased sexual satisfaction after cancer treatment. According to DSM-5 definition, the most common female sexual disorders were sexual interest/arousal disorder (70.9%), followed by genitopelvic pain/penetration disorder (60.0%), and orgasmic disorder (20.0%). In multiple logistic regression model, endometrial cancer diagnosis was the only independent factor predicting less influence of cancer treatment on FSD (OR 0.370; 95% CI 0.160, 0.856).ConclusionThe first study to use DSM-5 criteria for estimation of FSD prevalence. This enables clinicians to identify which women are actually needed to seek medical help. A prevalence of 43.7% of FSD associated with distress was found in a group of gynecologic cancer survivors with the most common being sexual interest/arousal disorder. Endometrial cancer survivors were at low risk for developing FSD after treatment.

Evaluation of sexual dysfunction and its predictive factors in female and male patients with rheumatoid arthritis

BackgroundRheumatoid arthritis (RA) is a common disabling joint disease affecting both males and females. Sexual dysfunction (SD) is a common association with RA. The aim of this work was to study the prevalence and predictors of sexual dysfunction in male and female patients with rheumatoid arthritis.ResultsThe mean age of female patients was 32.1 years and 39.7 years for males. The prevalence of sexual dysfunction was higher in RA female patients than controls, 62.1% versus 41.2% respectively (P ≤ 0.05). The prevalence of global sexual dysfunction was higher in RA male patients than controls, 63.8% versus 47.5% respectively (P ≤ 0.05). Predictors of sexual dysfunction in female RA patients were the number of children, BMI, disease duration, DAS score, HADs-D score, HAQ score, VAS score, joint deformity, and the number of drugs. Predictors of sexual dysfunction in male RA patients were age, disease duration, DAS score, HAQ score, VAS score, and the number of drugs.ConclusionSD is prevalent in RA patients. Disease activity, pain, depression, and disturbed quality of life affect nearly all domains of sexual functions in female and male patients.

Evaluation of Sexual Dysfunction in Female Patients with Fibromyalgia Syndrome

Objectives: The aim of our study is to determine the presence and quality of sexual function in women with fibromyalgia syndrome and to compare it with the normal population. Materials and methods: In our case-control study was conducted on sexually active 46 fibromyalgia patients who were diagnosed according to the American College of Rheumatology (ACR) criteria and 35 healthy control aged between 20-55. The data was collected with Beck Depression Inventory (BDI), Female Sexual Function Index (FSFI), Fibromyalgia Impact Questionnaire (FIQ) and Visual Analogue Scale (VAS). The clinical characteristics of both groups were compared and the relationships between FSFI and clinical parameters were evaluated. Results: Both groups were similar in terms of age, duration of marriage, number of children, family type and educational level. The mean duration of complaints in women with fibromyalgia was 5.62 (3.45) years, FIQ score was 59.8 (12.2) and VAS score was 7 (2). FSFI score was 13.2 (8.1) in group 1 and 32.1 (5.2) in group 2 (P<0.05). The mean scores of FIQ, BDI and VAS in group 1 were significantly higher than those in group 2 (P<0.05). In addition, a significant negative correlation was determined between the total FSFI score and FIQ and BDI scores in group 1. Conclusion: Negative effects of sexual dysfunction on female patients should be considered when evaluating fibromyalgia. It should be noted that sexual functon assessment must be a part of fibromyalgia syndrome treatment. Further studies are needed to elucidate the relationship between fibromyalgia and sexual dysfunction

Evaluation of Sexual Dysfunction in Patients Undergoing Hemodialysis Treatment

Evaluation of Sexual Dysfunction in Patients Undergoing Hemodialysis Treatment

MP28-21 MIRABEGRON FOR TREATMENT OF ERECTILE DYSFUNCTION CONCOMITANT WITH LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. A RANDOMIZED CONTROLLED TRIAL

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology & Evaluation (MP28)1 Sep 2021MP28-21 MIRABEGRON FOR TREATMENT OF ERECTILE DYSFUNCTION CONCOMITANT WITH LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. A RANDOMIZED CONTROLLED TRIAL Ramy Elbaz, Ahmed El-assmy, Mohamed H. Zahran, Abdelwahab Hashem, and Ahmed A. Shokeir Ramy ElbazRamy Elbaz More articles by this author , Ahmed El-assmyAhmed El-assmy More articles by this author , Mohamed H. ZahranMohamed H. Zahran More articles by this author , Abdelwahab HashemAbdelwahab Hashem More articles by this author , and Ahmed A. ShokeirAhmed A. Shokeir More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002025.21AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To assess the efficacy of mirabegron in treatment of erectile dysfunction (ED) that occurs in association with lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). METHODS: This single-blinded randomized controlled trial (RCT) was approved by the local Institutional Review Board (IRB) committee (IRB number: 18.07.214). Fifty-five sexually active BPH patients between 50-70 years with concomitant ED and LUTS were randomly allocated in two groups: the first received mirabegron 50 mg plus doxazosin 2 mg once daily (mirabegron group) and the second one received tolterodine 4 mg plus doxazosin 2 mg once daily (tolterodine group). The evaluation of sexual dysfunctions and LUTS was based on International Index of Erectile Function (IIEF-15) questionnaire -and its five subdomains-, Erection Hardness Score (EHS) questionnaire, International Prostate Symptom Score (IPSS)- and its storage, voiding and QOL subdomains- uroflometry and post voiding residual (PVR) assessed by ultrasonography. The therapeutic outcomes were assessed at 4, and 12 weeks compared to the baseline. RESULTS: Only, mirabegron group achieved significant improvement in sexual functions after 4 and 12 weeks including IIEF-15 total score, its erectile function (EF) domain, intercourse satisfaction domain, overall satisfaction domain and EHS questionnaire. By using 5 points or more difference from the baseline as a cut-off point of change, there was significant difference in change direction of IIEF-15 total score in favor of mirabegron group, after 4 weeks, IIEF-15 total score decreased in 4.2%, unchanged in 16.7% and improved in 79.1% in mirabegron group compared to 13%, 69.6% and 17.4%, respectively in tolterodine group (p <0.001), also, this significant difference between both groups was maintained after 12 weeks. Regarding the urinary characteristics, both group showed significant improvement in IPSS total score, its storage subdomain, QOL subdomain and PVR at both 4th and 12th week. In mirabegron group, IPSS total score improved from 18±6 at baseline to 12±4.6 and 11.±4.8 after 4 and 12 weeks, respectively (p <0.001), in tolterodine group, it improved from 17±5 at baseline to 13.7±4.4 and 12±5 after 4 and 12 weeks, respectively (p <0.001). However, only mirabegron group achieved significant improvement in voiding subdomain and Q max after both 4th and 12th week. CONCLUSIONS: Mirabegron –a β3 agonist- not only improves urinary characteristics in patients with LUTS secondary to BPH but also improves significantly the associated sexual and erectile characteristics. Source of Funding: Not present © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e489-e489 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ramy Elbaz More articles by this author Ahmed El-assmy More articles by this author Mohamed H. Zahran More articles by this author Abdelwahab Hashem More articles by this author Ahmed A. Shokeir More articles by this author Expand All Advertisement Loading ...

Experience of Vaginoplasty for Enhancement of Sexual Functioning in a Center in Turkey: A Before and After Study.

ObjectiveThe number of vaginal rejuvenation procedures for improvement of sexual function is dramatically increasing worldwide. The objective of this study was to present our experience with women who presented to our clinic with the complaint of sexual dysfunction or desire to enhance sexual function or orgasm.MethodsDemographic and descriptive data of the patients were evaluated. In addition, sexual dysfunction of the patients who underwent vaginoplasty in our center were evaluated before and after vaginoplasty procedure using Golombok Rust Inventory of Sexual Satisfaction (GRISS) scale and the scores were compared before and after the procedure, which is used in the evaluation of sexual dysfunction by relationship counsellors and clinics.ResultsA total of 250 women who described a sensation of a wide or floppy vagina with lost or decreased ability to achieve orgasm were included in the study. The mean age of the patients was 38.51±9.126 years. Of all women, 85.2% were college graduates. A history of normal vaginal delivery was found in 77.8% of the participants. The mean GRISS scores of “Infrequency”, “Non-communication”, “Dissatisfaction”, “Non-sensuality”, “Avoidance”, “Anorgasmia” and “overall GRISS” scores were statistically significantly decreased, while the mean vaginismus score was significantly increased (p<0.01).ConclusionHighly satisfying outcomes regarding patient satisfaction were obtained from vaginoplasty procedures that we have performed.

Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies

Objective:Physiological and/or psychological problems that affect the quality of life of the patients occur depending on the diagnosis and treatment of hematological malignancies. Cancer treatment causes sexual problems such as infertility, vaginal dryness, and erectile dysfunction in the patients. Erectile dysfunction and loss of sexual desire are the most common sexual problems of men, while dyspareunia and loss of sexual desire are the most common sexual problems of women. This descriptive study was carried out to evaluate sexual problems and affecting factors in the patients with hematological cancer.Methods:Between July 1, 2011, and July 31, 2011, 45 sexually active patients who volunteered to participate in the study and whose written consents were obtained were included in the study. The data of the study were collected using the descriptive characteristics form prepared by the researchers based on the relevant literature and the Arizona Sexual Experiences Scale (ASEX). The scale scores range from 5 to 30 and a score of >11 above indicates sexual dysfunction.Results:Sexual dysfunction was observed in 62.2% of the patients. About 80.0% of women and 57.1% of men had sexual dysfunction. Sexual dysfunction was observed to be highest between the ages of 52–71 (81.2%) years. The mean total ASEX score was 15.90 ± 4.25 in women and 13.34 ± 5.37 in men. The ability to reach orgasm subscale score was found to differ by gender in the ASEX scale (P < 0.05).Conclusions:The prevalence of sexual dysfunction is high in the patients with hematological malignancies. It is recommended to evaluate these patients in terms of the presence of sexual dysfunction, as in the patients with other chronic diseases.

Sexual dysfunction in Neuro-Behcet’s disease

The aim of the study was evaluation of sexual dysfunction in neuro-Behcet’s disease (NBD). A total of 25 patients with NBD, 22 patients with Behçet’s disease (BD) without neurologic involvement (BDWONI) and 19 persons in control group were prospectively included in the study. We collected all demographic data. A semi-structured interview guided by a Arizona sexual experience scale (ASEX) questionnaire, Beck Depression Inventory and Beck Anxiety Inventory was applied to all of the patients. The sexual dysfunction was significantly higher in patients with NBD (47.9%) compared to patients with BDWONI (35.4%) and control group (16.7%) (p = 0.001). The score of total ASEX, drive, aurosal, vaginal lubrication/penil erection and satisfaction from orgasm were significantly higher in patients with NBD than healthy control group, statistically. Just arousal and lubrication/penile erection scores were significantly higher in NBD group than BDWONI group. Female/Male ratio regarding sexual dysfunction was 43.5/56.5, 29.4/70.6, 62.5/37.5 in NBD, BDWONI and healthy control group, respectively (0 = 0.027). NBD had a negative effect on sexuality in all but especially on arousal and vaginal lubrication/penil erection function based on ASEX questionnaire. Moreover, male sexuality was more affected by BD than female sexuality. Further researches using larger sample sizes are needed to clarify the issues.

Evaluation of sexual dysfunction and its associated risk factors in the male partners of the infertile couples using International Index of Erectile Function

Objective:Sexual dysfunction is a major health concern in infertile men. This research aims to evaluate the sexual dysfunction and its associated risk factors in the male partners of infertile couples.Materials and Methods:The cross-sectional study was performed on 204 male partners of infertile couples that were referred to Fatemeh Zahra Infertility & Reproductive Center, Babol, Iran, in 2015. Sexual dysfunction was evaluated using The International Index of Erectile Function (IIEF). Logistic and linear regression tests were used for statis¬tical analyses. Statistical significance was considered with a p value less than 0.05.Results:The mean total IIEF score was 58.30±8.52. The lowest mean of IIEF domains was related to sexual desire and then orgasmic function in the male partners of the infertile couples. Erectile function contributed to the greatest amount of unique variance in the model for sexual function (p<0.001, R2=69.8%). The strongest correlation value was between the domains of overall satisfaction and intercourse satisfaction. There was a positive statistically significant association between sexual function with wife marital intimacy (p<0.002) and wife sexual function (p<0.001). There was a significant association between sexual dysfunction with job conditions (p<0.037, OR=0.094), and coitus count (p<0.009, OR=6.146). After adjusting for other variables, there was a significant association between sexual function and wife sexual function (p<0.005). Also, after adjusting for other variables, there was a significant association between sexual dysfunction and coitus count (p<0.004, OR=2.496), and job condition (p<0.046, OR=0.081).Conclusion:By considering sexual dysfunction and some related factors, early screening is required for distinguishing predictor factors of sexual dysfunction.

Evaluation of sexual dysfunction in Brazilian women with breast cancer: partial results

Objective: To assess the pattern of sexual performance in women treated for breast cancer. Methods: This is a cross-sectional study on women treated for breast cancer. Inclusion criteria: to have undergone the first-line therapy for cancer and the cancer not being classified as stage IV. Data on cancer were collected by the analysis of medical records. For the evaluation of sexual performance, women were submitted to individual interviews, with the application of the Quociente Sexual – Versão Feminina (QS F) questionnaire. Sexual performance was classified as: bad, unfavorable, regular, good, and excellent. The diagnosis of sexual dysfunction was established to women with score ≤ 60. For descriptive analyses, absolute (n) and relative (%) frequencies were performed, and for the comparison between the quantitative variables the Student’s t-test was used. Results: 31 women with a mean age of 55.2 years were included, 35% were classified as clinical stage II, 84% underwent conservative surgery, 65% underwent chemotherapy, and 80% used endocrinotherapy. Regarding sexual performance, 62% spontaneously think about sex, 35% are always interested in sex, and 51.7% have some degree of pain during intercourse. After calculating the score, it was concluded that 6.5% had bad sexual performance; 19.4%, unfavorable; 19.4%, regular; 41.9%, good; and 12.8%, excellent. The mean score was 58.7 points (standard deviation = 21.4, median of 64, minimum of 16, and maximum of 90 points), and 45.2% of women were diagnosed with sexual dysfunction. The provided treatments and the length of follow-up did not have a significant correlation with sexual performance. Conclusion: Most women treated for breast cancer had sexual performance classified as “good and excellent,” although a significant percentage had a diagnosis of sexual dysfunction.

Evaluation of sexual dysfunctions among women living with a partner in Ouagadougou, Burkina.

To study the sexual dysfunctions of women living with a partnerin relationship in the city of Ouagadougou. This was a descriptive, and analytical cross-sectional study collectedwith prospective data collection over the a period of seven (07-) months period from March 1st through November 30th, 2016,. by interviewing It consisted of collecting from 633 women living with a partner in relationship in Ouagadougou data aboutn their sex livfes. The data werehas been processed and analyzed with epi-info software, in version 3.5.3. Statistical tests (Chi-square and, Fisher's exact tests) were used to assess the association between the different variables at athe 5% significance level of 5%. The study participation rate was 90.8%. In our study, 84.5% (n=or 486) women reported having at least one sexual dysfunction in their lifetime. Of those surveyed, 84.5% (486/575) had anorgasmia, 64.3% (370/575) had dyspareunia, 35.8% (206/575) had an problems of arousalexcitement disorder, and 35.1% had (202/575) frigidity. In addition,There were 116 of them (20.3%) hadwith lowdecreased libidosexual desire and 0.7% (4/575) with vaginismus. Female circumcision was the main factor associated with the sexual dysfunction of the respondents. Dyspareunia was 4.2 times more common in women with genital excisioned women than in uncircumcised women The sSexual dysfunction is frequent amongof a womean living within a partnercouple in the city of Ouagadougou is frequent. Because excision is one of the factors [[[The leading factor]]] found in the occurrence of sexual dysfunction in women, hence the need to proscribe this harmful practice must be proscribed in our societies.

SUN-207 Hot Flashes, Flushing, and Sweating in a Middle-Aged Man with Pituitary Macroadenoma

Background: Vasomotor symptoms such as hot flashes and sweating, typical of the menopausal syndrome in women, are less commonly seen in males after loss of testicular function. We present an interesting case of a middle-aged man who was evaluated for progressive episodes of hot flashes, sweating and flushing and was eventually diagnosed with pituitary macroadenoma causing secondary hypogonadism. Clinical Case: A 59 y.o. male was referred endocrinology clinic with intermittent episodes of hot flashes and sweating over the last 2 years. He has had progressive episodes of feeling warm, associated with some flushing, and then transient profuse sweating, usually lasting no more than several minutes. His only other medical problem has been chronic recurrent gout requiring Allopurinol 300 mg daily, Probenecid 500mg twice daily and Colchicine 0.6mg twice daily to prevent gout attacks. He denied any headaches, palpitations, feeling tremulous, no vision symptoms, no breast enlargement or loss of body hair, no constipation or diarrhea. Physical exam was significant for paucity of facial and body hair, and no evidence of gynecomastia. He had an episode in the office visit where he became flushed, diaphoretic, his blood pressure was 120/80 and he did not have tachycardia. Lab studies revealed Prolactin= 19 (n= 2-18 pg/dL), Cortisol 8.6 (6-27 ug/dl), Total Testosterone = 22 (n=250-1100 ng/dL), LH = <1 (n=1.5-9.3 mlU/ml), free T4 0.6 (ref 0.6-1.6 ng/dl) with TSH 1.51 (ref: 0.34 -3.00 uIU/ml), IGF-1 = 49 (34-232 ng/dl), Total metanephrines urine 654 ( 233-716 (Normotensive)), VMA = 3.6 (<8.0 mg/24 h) suggestive of secondary hypogonadism with elevated prolactin and low LH. MRI of the brain revealed mass of the sella extending into the suprasellar region measuring up to 2.0 x 2.3 x 1.8 cm. He then underwent endoscopic transsphenoidal resection of pituitary tumor and histopathology revealed null cell adenoma with widespread oncocytic changes consistent with an oncocytoma. On follow up visit in 1 month, his debilitating sweats have diminished significantly but not disappeared. Conclusion: Hot flushes are common in men who are acutely hypogonadal after orchiectomy or testicular injury, but it is an unusual symptom in patients with hypogonadism secondary to pituitary tumors. There are case reports of pituitary adenoma diagnosed through evaluation of sexual dysfunction and frequent hot flashes. This case illustrates the importance of considering broad etiologies when evaluating new onset hot flashes in middle-aged men, especially in the absence of other presenting features of pituitary macroadenoma and when symptoms of hypogonadism (like erectile dysfunction, low libido, impaired concentration and fatigue) go unreported to physicians.

Evaluation of sexual dysfunction and quality of life in patients with severe mental illness: A cross-sectional study from a tertiary care center in Chhattisgarh.

Background:Sexual dysfunctions (SDs) are common and lead to psychological distress and impair quality of life (QOL). However, little attention has been paid to explore SD in severe mental illnesses (SMIs). Hence, this study aimed to evaluate the occurrence of SD and its impact on the QOL in persons suffering from schizophrenia, bipolar disorder, and depression and compare it with healthy controls.Materials and Methods:In this cross-sectional study, 79 clinically stable patients and 50 healthy controls underwent evaluation for SD on the Arizona Sexual Experience Scale, and their QOL was measured using the WHO QOL-BREF scale. Chi-square test was used for the categorical variables, whereas comparison of continuous variables was done by t-test with post hoc corrections.Results:Compared to healthy controls, patients with depression had significantly higher rates of SD in the domain of obtaining penile erection (P = 0.019), ability to reach orgasm (P = 0.03), and satisfaction from orgasm (P = 0.01). Patients with schizophrenia had higher rates of problems in achieving arousal (P < 0.01), penile erection (P = 0.03), and satisfaction from orgasm (P = 0.03), whereas those with bipolar disorder only differed significantly on the domain of ability to reach orgasm (P = 0.03). However, patients fared better than the controls on various domains of QOL (except social domain).Conclusion:A significant number of patients with SMI suffer from SD. Hence, it should be made a routine practice to evaluate and address the problem of SDs in patients with SMI.